Ara
Toplam kayıt 3, listelenen: 1-3
Combined metabolic activators improve metabolic functions in the animal models of neurodegenerative diseases
(Elsevier Inc., 2023)
Background: Neurodegenerative diseases (NDDs), including Alzheimer's disease (AD) and Parkinson's disease (PD), are associated with metabolic abnormalities. Integrative analysis of human clinical data and animal studies ...
Combined metabolic activators improve cognitive functions in Alzheimer's disease patients: A randomised, double-blinded, placebo-controlled phase-II trial
(BioMed Central Ltd, 2023)
Background: Alzheimer’s disease (AD) is associated with metabolic abnormalities linked to critical elements of neurodegeneration. We recently administered combined metabolic activators (CMA) to the AD rat model and observed ...
The functional role of the pulvinar in discriminating between objective and subjective cognitive impairment in major depressive disorder
(John Wiley and Sons Inc, 2024)
INTRODUCTIONEmotionally driven cognitive complaints represent a major diagnostic challenge for clinicians and indicate the importance of objective confirmation of the accuracy of depressive patients' descriptions of their ...